July 3, 2023/Genomic Medicine

Genetics of Parkinson’s Disease in Latino Populations (Podcast)

Consortium is uncovering risk factors that spur disease development in an understudied group


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Approximately 10 million people around the world have Parkinson’s disease. Yet most of the genetic studies on this progressive disorder have been conducted in populations of European and Asian ancestry. Very little is known about the genes that may influence Parkinson’s disease risk in Latinos.

Ignacio Mata, PhD, assistant staff in the Genomic Medicine Institute within Cleveland Clinic’s Lerner Research Institute, is working to change that as the U.S. coordinator of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD).

“It’s a very complex disease, and probably every patient has a different combination of variants in different genes,” says Dr. Mata. “That’s why I think it’s very hard to understand the cause and also to slow or stop it.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Mata discusses genetics in Parkinson’s disease and the role of LARGE-PD, a multicenter collaboration. He covers:

  • The interplay of environmental triggers and genetic predisposition for Parkinson’s
  • The inception and goals of LARGE-PD
  • Results of studies investigating specific genes and genome-wide associations
  • Recommendations on who should undergo genetic testing for Parkinson’s
  • Genetic research initiatives for other underserved populations, including the Black community and Southeast Asians
  • Advice for genetic researchers who want to study Parkinson’s in underserved populations

Click the podcast player above to listen to the 27-minute episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.


Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: What I’d like to know now is what have you found? What surprised you?

Dr. Mata: The latest [study] we have done is a genome-wide association study, or GWAS, where you compare a very large number of cases with the disease that you are trying to study and a large number of controls that are matched by age, gender and hopefully where they’re coming from in terms of ancestry. And then you look for variants that occur at a different frequency between the two groups. If a variant is more frequent in cases, then it might be a risk variant. In contrast, if a variant is more common in controls, maybe it’s a protective variant.

This association study has allowed us to really start to understand what the genetic architecture of Parkinson’s disease is in Latinos. And we know that it is about 80% similar to Europeans, but there are new genes we have identified that are mostly associated with indigenous and African ancestries.

Dr. Stevens: And what’s the number of causal genes?

Dr. Mata: In total for Parkinson’s disease, we have about 24 that are familial. If you have a variant in those genes, you are most likely going to develop the disease. We call these causal variants. And then there are probably over 100 we have identified that are risk variants. This means that these variants do not cause Parkinson’s but increase a person’s risk. And most of us carry several of these variants. We then use something called a polygenic risk score in which we calculate how many of each type of variant someone carries and this tells us their total risk by comparing all the variants.


Related Articles

Is the MTHFR Gene Mutation Associated With Thrombosis?

The relationship between MTHFR variants and thrombosis risk is a complex issue, but current evidence points to no association between the most common variants and an elevated risk

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023/Genomic Medicine
Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

August 17, 2023/Genomic Medicine
Parkinson’s Disease Research in Women (Podcast)

Studying gender-specific health factors promises new insight into diagnosis, prognosis, treatment

February 22, 2023/Genomic Medicine/Research
Determining Autism, Cancer Risk in Patients with PTEN Hamartoma Tumor Syndrome

Cleveland Clinic researchers receive $2 million grant from the National Institutes of Health

22-NEU-2638258 genetics_650x450
August 8, 2022/Genomic Medicine
The Case for a Precision Medicine Approach to Training Epilepsy Clinicians

New Cleveland Clinic fellowship fosters expertise in the genetics of epilepsy

21-URL-2361635 CQD 650×450
June 23, 2022/Genomic Medicine
Managing Refractory Hypocalcemia in an Asymptomatic Patient During Pregnancy

Renal genetic testing confirms diagnosis, guides management

April 6, 2022/Genomic Medicine
Prediction Model Aids in the Early Diagnosis of Dravet Syndrome

Integrates genetic and clinical data to distinguish from GEFS+ and milder epilepsies

January 19, 2022/Genomic Medicine
Launch of Cleveland Clinic Brain Study Marks Unprecedented Effort to Disrupt Neurological Diseases

First-of-kind study aims to enable prevention of brain disorders before symptoms appear